Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Clinical safety of ranibizumab in age-related macular degeneration.

Authors
Type
Published Article
Journal
Expert Opinion on Drug Safety
1744-764X
Publisher
Informa UK (Taylor & Francis)
Publication Date
Volume
9
Issue
1
Pages
149–165
Identifiers
DOI: 10.1517/14740330903418422
PMID: 20001757
Source
Medline
License
Unknown

Abstract

Although further studies to investigate the risk of stroke with ranibizumab therapy are required, repeated intravitreal ranibizumab was well tolerated and not associated with clinically significant safety risks during up to 2 years of treatment.

Statistics

Seen <100 times